A new systematic literature review shows that cannabinoid-based therapy is beneficial for irritable bowel disease (IBD), but the heterogeneity of dosing, mode of administration, and study design limits the ability to draw firm conclusions. The review, published in Cureus, notes the need for high-quality, randomized, placebo-controlled trials to determine the appropriate dose and ideal mode…

A new study has assessed the demographics, prevalence, and perceptions regarding the use of medical cannabis among patients with inflammatory bowel disease (IBD). The study, published in the International Journal of Environmental Research and Public Health, found that just under half of the patients who use cannabis for IBD had discussed it with their physician.…

Use of medical cannabis in patients with inflammatory bowel disease (IBD) was linked to significantly reduced disease activity and increased patient weight in a prospective, observational study reported in the European Journal of Gastroenterology and Hepatology. The study included 127 patients with IBD treated with medical cannabis using an average dose 31±15 g/month, or 21…

Adults hospitalized with Crohn’s disease (CD) or ulcerative colitis (UC) who reported cannabis use had a lower frequency of colorectal cancer, parenteral nutrition, and anemia compared to nonusers, according to a retrospective analysis reported in the June issue of Annals of Translational Medicine.  The study included data from the Nationwide Inpatient Sample on 6,002 patients…

Patients who used cannabis were at significantly reduced risk for hospital-acquired Clostridioides difficile infection (CDI) compared with nonusers, according to a large study published in Anaerobe.   Researchers analyzed data from nearly 60,000 hospitalizations the Nationwide Inpatient Sample 2014 to compare outcomes in patients with and without cannabis use  disorder (CUD) as documented in ICD-9-CM codes. …